Recombinant Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 (TAB2), Truncated

Cat.No	ACP11704	Target Name	TAB2
Form	Lyophilized powder	Expression System	Custom Production. Please inquire and provide the desire expression system.
Expression Range	401-693	Protein Length	Partial
Purity	>85% (SDS-PAGE)	Storage Buffer	5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Cat.No

ACP11704

Target Name

TAB2

Form

Lyophilized powder

Expression System

Custom Production. Please inquire and provide the desire expression system.

Expression Range

401-693

Protein Length

Partial

Purity

>85% (SDS-PAGE)

Storage Buffer

5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Target Species	Human	Uniprot ID	Q9NYJ8

Background Information

Uniprot Id

Q9NYJ8
Target Species

Human
Target Name

TAB2
Target Full Name

TGF-beta-activated kinase 1 and MAP3K7-binding protein 2
Target Function

Adapter required to activate the JNK and NF-kappa-B signaling pathways through the specific recognition of 'Lys-63'-linked polyubiquitin chains by its RanBP2-type zinc finger (NZF). Acts as an adapter linking MAP3K7/TAK1 and TRAF6 to 'Lys-63'-linked polyubiquitin chains. The RanBP2-type zinc finger (NZF) specifically recognizes Lys-63'-linked polyubiquitin chains unanchored or anchored to the substrate proteins such as RIPK1/RIP1: this acts as a scaffold to organize a large signaling complex to promote autophosphorylation of MAP3K7/TAK1, and subsequent activation of I-kappa-B-kinase (IKK) core complex by MAP3K7/TAK1. Regulates the IL1-mediated translocation of NCOR1 out of the nucleus. Involved in heart development.
Target Involvement

Congenital heart defects, multiple types, 2 (CHTD2)
Target Subcellular Location

Membrane; Peripheral membrane protein. Cytoplasm, cytosol.
Target Tissue Specificity

Widely expressed. In the embryo, expressed in the ventricular trabeculae, endothelial cells of the conotruncal cushions of the outflow tract and in the endothelial cells lining the developing aortic valves.
Target Research Area

Immunology
Target Synonyms

CHTD2; FLJ21885; KIAA0733; MAP3K7IP2; Mitogen activated protein kinase kinase kinase 7 interacting protein 2; Mitogen-activated protein kinase kinase kinase 7-interacting protein 2; OTTHUMP00000040125; TAB 2; TAB-2; Tab2; TAB2_HUMAN; TAK1 binding protein 2; TAK1-binding protein 2; TGF beta activated kinase 1/MAP3K7 binding protein 2; TGF-beta-activated kinase 1 and MAP3K7-binding protein 2; TGF-beta-activated kinase 1-binding protein 2
Target Background

The protein encoded by this gene is an activator of MAP3K7/TAK1, which is required for for the IL-1 induced activation of nuclear factor kappaB and MAPK8/JNK. This protein forms a kinase complex with TRAF6, MAP3K7 and TAB1, and it thus serves as an adaptor that links MAP3K7 and TRAF6. This protein, along with TAB1 and MAP3K7, also participates in the signal transduction induced by TNFSF11/RANKl through the activation of the receptor activator of NF-kappaB (TNFRSF11A/RANK), which may regulate the development and function of osteoclasts. Studies of the related mouse protein indicate that it functions to protect against liver damage caused by chemical stressors. Mutations in this gene cause congenital heart defects, multiple types, 2 (CHTD2). Alternative splicing results in multiple transcript variants.

Recombinant Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 (TAB2), Truncated

Specifications

Immunogen Information

Inquire Recombinant Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 (TAB2), Truncated Now

Related Products